What are the common side effects of Tarlatamab-Imdelltra?

Tarlatamab-Imdelltra is the world's first bispecific T cell adapter drug targeting DLL3, and its clinical value lies in bringing new treatment possibilities to patients with small cell lung cancer (ES-SCLC). But like most immunotherapy drugs, while it exerts anti-tumor effects, it may also cause a series of adverse reactions, which requires joint attention and management by patients and doctors.

First of all, a common adverse reaction that requires careful monitoring is cytokine release syndrome (CRS). This is due to the large-scale activation of the immune system, which leads to the rapid release of a variety of inflammatory factors, resulting in symptoms such as fever, chills, hypotension and even difficulty breathing. Although most cases are mild to moderate, close observation and timely intervention are still required.

Secondly, patients may experience fatigue, fever, abnormal taste, loss of appetite, nausea, constipation, musculoskeletal pain and other symptoms during talatumumab treatment. These side effects can usually be alleviated through supportive care or symptomatic treatment, but they may affect the quality of life of patients on long-term medication and therefore require individualized management.

In terms of hematology, talatumumab can cause laboratory abnormalities such as anemia, lymphopenia, neutropenia, and thrombocytopenia, which means that the patient's immunity and hematopoietic function may be affected. Clinically, it is necessary to regularly monitor blood routine and adjust the dose or provide auxiliary treatment according to the situation.

In addition, some patients have electrolyte disorders, such as decreased serum sodium, decreased serum potassium, and increased liver function indicators, such as increased aspartate aminotransferase and alanine aminotransferase. For these changes, doctors need to conduct routine laboratory tests during treatment to detect and deal with abnormalities in a timely manner.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html